Masafumi Nishino

Evidence that the Degree and Duration of Acid Suppression are Related to <i>Helicobacter pylori</i> Eradication by Triple Therapy

Mitsushige Sugimoto, Takahisa Furuta, Naohito Shirai et al. · Helicobacter · 2007 · 147 citations

Polydom Is an Extracellular Matrix Protein Involved in Lymphatic Vessel Remodeling

Nanami Morooka, Sugiko Futaki, Masafumi Nishino et al. · Circulation Research · 2017 · 95 citations · Full text

Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy

Naohito Shirai, Mitsushige Sugimoto, Chise Kodaira et al. · European Journal of Clinical Pharmacology · 2007 · 90 citations

Helicobacter Pylori Infection, Antibiotics, Standard Triple Therapy +5

Rabeprazole 10 mg q.d.s. decreases 24‐h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming <scp>CYP</scp>2<scp>C</scp>19 genotype

Mitsushige Sugimoto, Naohito Shirai, Masafumi Nishino et al. · Alimentary Pharmacology & Therapeutics · 2012 · 59 citations

Effect of<i>MDR1</i>C3435T polymorphism on cure rates of<i>Helicobacter pylori</i>infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to<i>CYP </i>2C19 genotypes and 23S rRNA genotypes of<i>H. pylori</i>

Takahisa Furuta, Mitsushige Sugimoto, Naohito Shirai et al. · Alimentary Pharmacology & Therapeutics · 2007 · 46 citations · Full text